Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Florbetapir for Poststroke Cognitive Impairment and Dementia
NCT02813434Phase 3Completed
- Sponsor
- CHU Amiens-Picardie
- Start
- Sep 2014
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Florbetapir in post-stroke cognitive impairment (PSCI) and Dementia, sponsored by CHU Amiens-Picardie. Primary endpoint: Presence of positive amyloid retention at 12 months. Started Sep 2014; status: completed.
02
Drugs
Florbetapir
03
Conditions
post-stroke cognitive impairment (PSCI)Dementia
Beyond the preview
Go deeper on NCT02813434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02813434.